USTR will hold a public hearing on September 22, 2026 regarding a Section 301 investigation into Germany’s policies related to persistent underpayment for innovative pharmaceutical products. The investigation examines German acts and practices that may constitute unfair trade practices affecting U.S. pharmaceutical market access. This is a formal trade remedy proceeding that could lead to retaliatory tariffs or other measures.
Official NewsUstrUnited States
Public Hearing on Section 301 Investigation of Germany’s Underpayment for Innovative Pharmaceuticals
Original: Public Hearing Regarding Section 301 Investigation of Germany’s Persistent Underpayment for Innovative Pharmaceutical Products